An initiative has been launched to ensure private healthcare data is recorded in the same way as NHS data in England, with the aim of improving consistency across the system. The Acute Data Alignment Programme (ADAPt) aims to integrate data on privately funded healthcare into NHS systems and standards for the first time.
Digital solutions supporting a continuum of care across a range of health and care services can relieve the pressure on governments to provide more cost-effective health and care systems by improving utilisation of healthcare and health outcomes. In this context the challenges are to network, lead and facilitate health systems research, innovation and digitisation in view of addressing key areas of interventions in health and care services including health promotion and disease prevention.
| Location: | Erlangen, Germany |
| Job Type: | Full-Time |
| Employer: | Siemens Healthineers™ |
Siemens Healthineers and KinetiCor present at the 26th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM) in Paris (June 16 - 21, 2018) the joint results of their strategic agreement to co-develop technologies for patient monitoring and correction of patient motion in MRI exams. The strategic collaboration of both companies involves the joint development of an MRI in-bore camera system to expand precision medicine.
9 - 11 April 2019, Berlin, Germany.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that it has acquired Remote Diagnostic Technologies (RDT), a UK-based leading innovator of advanced solutions for the pre-hospital market providing monitoring, cardiac therapy and data management. RDT's portfolio of comprehensive connected emergency care solutions will complement Philips' Therapeutic Care business and strengthen its leadership position in the EUR 1.4 billion resuscitation and emergency care market.
The University of Tokyo's Research Center for Advanced Science and Technology (RCAST), Fujitsu Limited, and Kowa Company Ltd. today announced that using IT-based drug discovery technologies, which entails computer-based virtual design and evaluation, they have successfully created new small molecule compounds that can inhibit cancer-causing "target proteins," and that demonstrate promise against cancers that have shown resistance to existing drugs.